Clifford Goodrich, MD
Glaucoma Specialist · Dallas, TXNPI 1154703676
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.5% of the total across 34 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 34.9% of the total. 2023 is the largest year on record at $480, 2.3 times the $210 reported in 2019. That places this record below the midpoint for glaucoma specialist clinicians in TX, where the typical reported total is $2,605.
Across 34 payments — averaging $28.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$334
- Ellexiscience$157
- Alcon$155
- Bausch & Lomb Americas Inc.$149
- Glaukos Corporation$96
- Novartis$35
- plus $32 from 1 others
What the payments were for
- Food & beverage$91495%
- Education$435%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $334 |
| Ellexiscience | 1 | $157 |
| Alcon | 4 | $155 |
| Bausch & Lomb Americas Inc. | 10 | $149 |
| Glaukos Corporation | 1 | $96 |
| Novartis | 1 | $35 |
| Sun Pharmaceutical Industries Inc. | 1 | $32 |
How this compares
$958 in reported general payments places this provider in the 25th percentile of 31 glaucoma specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 106 | $45,141 |
| VyzultaLatanoprostene Bunod | 89 | $37,600 |
| RocklatanNetarsudil Mesylat/Latanoprost | 75 | $29,190 |
| RestasisCyclosporine | 30 | $25,793 |
| Alphagan PBrimonidine Tartrate | 42 | $16,793 |
| CombiganBrimonidine Tartrate/Timolol | 39 | $14,350 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 121 | $13,374 |
| Brimonidine Tartrate | 217 | $12,675 |
| RhopressaNetarsudil Mesylate | 25 | $12,320 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 607 | $9,641 |
| Cyclosporine | 15 | $8,906 |
| Latanoprost | 808 | $7,884 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 33 | $7,759 |
| Travoprost | 49 | $7,756 |
| Dorzolamide Hcl | 107 | $2,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $334 | $102,078217 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $149 | $37,60089 claims |
| AlconSimbrinza | $155 | $7,75933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 31 glaucoma specialist providers in Texas.
Other glaucoma specialist in Dallas
- Shivani KamatDallas$164K
- Karanjit KoonerDallas$3K
- Jess WhitsonDallas$923
- Mugen LiuDallas$677
- Robert FeldmanHouston$31K
- Amenze OriaifoAustin$18K
- David LeeHouston$17K
- Nicholas GurneyFt Worth$13K
- Patrick WuHouston$11K
- Irina VoloskoAustin$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.